BioSpace News Archive

Amneal and Impax to Marry, Creating the 5th Larges

Business

Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson

Syndesi will work to modulate the synaptic vesicle protein SV2A.

February 9, 2018

·

2 min read

·

Mark Terry

Teva’s CGRP Migraine Med Hits a Stumbling Block

It’s starting to feel like Teva can’t catch a break.

February 9, 2018

·

1 min read

Business

Elekta Fosters Innovation Through Nobel Center Partnership

The Nobel Center, an initiative within the Nobel Foundation, will operate in the spirit of the Nobel Prize.

February 9, 2018

·

3 min read

Business

ImmunoGen Reports Pipeline Progress and 2017 Operating Results

Revenues for the year ended December 31, 2017 were $115.4 million, compared to $48.6 million for the year ended December 31, 2016.

February 9, 2018

·

12 min read

Trillium Therapeutics to Present at Investor and Scientific Conferences in the First Quarter

Trillium announced today that the company is scheduled to present an update on the company’s programs and progress at several upcoming conferences.

February 9, 2018

·

3 min read

Biotech Beach

Tandem Diabetes Care Announces Pricing of $60 Million Underwritten Public Offering of Common Stock

The gross proceeds to Tandem from this offering are expected to be $60 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tandem.

February 9, 2018

·

4 min read

Policy

FDA Extends PDUFA Action Date for Salix Pharma’s PLENVU

The PDUFA action date has been extended to allow the FDA more time to review additional data that was recently provided at its request.

February 9, 2018

·

3 min read

Policy

Medac Pharma Announces the Patent Trial and Appeal Board Upheld Patents on Rasuvo (Single Dose Auto-Injection of Methotrexate)

This ruling ends the challenge brought by Koios Pharmaceuticals LLC.

February 9, 2018

·

1 min read

Drug Development

Aerpio Pharmaceuticals Completes Patient Enrollment in TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy

Aerpio announced today the completion of patient enrollment in the company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate AKB-9778 for patients with moderate to severe non-proliferative diabetic retinopathy.

February 9, 2018

·

3 min read

Business

Emmaus Medical, Inc. Selects AmerisourceBergen to Support the Launch of Endari (L-glutamine oral powder)

As part of this partnership, Emmaus will leverage the breadth of AmerisourceBergen’s integrated commercialization solutions to support adherence and realize the best possible outcomes for patients.

February 9, 2018

·

7 min read